WEBULL
WebtradeDownload

Arcus Biosciences (RCUS) Sets Casdatifan Data Event As Undervalued Narrative Faces A Test

Simply Wall St · 2d ago

Arcus Biosciences (RCUS) just put a firm date on its next catalyst, telling investors it will unveil new ARC-20 data on kidney cancer drug casdatifan at an October 20 event in New York.

Arcus Biosciences has seen its share price slip in the near term, with the stock down 5.04% over the past day and 20.62% over 30 days, even as total shareholder return sits at 102.59% over one year and 38.76% across three years. This suggests long-term holders have been rewarded while shorter-term momentum has faded ahead of the casdatifan data catalyst.

Capitalize on the coming casdatifan readout by comparing Arcus Biosciences with other oncology names that screen well on fundamentals through a curated set of 16 high quality undiscovered gems.

Bulls see Arcus Biosciences as a beaten up oncology platform with a fresh casdatifan catalyst. Bears see a loss-making biotech that ran too far. Which story does current pricing lean toward as the numbers are lined up next?

Most Popular Narrative: 34% Undervalued

Arcus Biosciences closed at $25.06 while the most followed narrative pegs fair value near $38.00, so the story assumes investors are underpaying for casdatifan and the broader oncology pipeline today.

Arcus Biosciences is prioritizing the launch of its late-stage development program for the HIF-2 alpha inhibitor, casdatifan. The candidate has shown significant efficacy differentiation relative to existing market competitors. This may enhance future revenue through competitive advantages in the RCC market.

See why 10 investors see Arcus Biosciences as 34% undervalued.

Result: Fair Value of $38 (UNDERVALUED)

Still, if upcoming casdatifan data disappoints or regulators slow key programs, the 34% undervalued story on Arcus Biosciences could unwind quickly.

Find out about the key risks to this Arcus Biosciences narrative.

Another View: What Multiples Say About Arcus Biosciences

The DCF work suggests Arcus Biosciences trades well below an $80.55 future cash flow value, yet the simple sales-based check tells a more demanding story. The stock changes hands at a P/S of 27.3x compared with 12.5x for US biotechs, while the fair ratio points closer to 0.1x.

That gap means investors are already paying a steep upfront price for unproven oncology programs, even if the SWS DCF model argues the cash flow potential supports it. The question for anyone watching casdatifan is which signal to trust when expectations and uncertainty both run high.

See what the numbers say about this price — find out in our valuation breakdown.

NYSE:RCUS P/S Ratio as at Sep 2026
NYSE:RCUS P/S Ratio as at Sep 2026

Next Steps

Mixed sentiment runs through the Arcus Biosciences story right now, so move quickly, review the full risk and reward breakdown, and decide where you land with the 2 key rewards and 3 important warning signs.

Ready For More Ideas Beyond Arcus Biosciences?

If the Arcus Biosciences setup has your attention, do not stop at a single ticker. Broader context often reveals opportunities that individual headlines miss.

Use the Simply Wall Street screener to uncover stocks that match your risk tolerance, income needs, and preference for quality, before others spot them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.